Raymond James & Associates Syndax Pharmaceuticals Inc Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$5.43 - $9.22 $81,450 - $138,300	-15,000 Closed	0 $0
Q2 2019 Aug 06, 2019	SELL	$4.9 - $9.31 $24,500 - $46,550	-5,000 Reduced 25.0%	15,000 $140,000
Q1 2019 May 06, 2019	SELL	$4.26 - $6.86 $8,520 - $13,720	-2,000 Reduced 9.09%	20,000 $105,000
Q4 2018 Feb 11, 2019	BUY	$3.6 - $8.42 $79,200 - $185,240	22,000 New	22,000 $98,000

229

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $946M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.